GC Biopharma Corp. is a pharmaceutical and biotechnology company that manufactures and sells blood products, vaccines, prescription drugs, and over-the-counter medications. Its core business segments include blood products, such as immunoglobulins and albumin, and vaccines, including influenza and varicella formulations. Key products include ALYGLO, an intravenous immunoglobulin approved by the FDA in 2023 and launched in the United States in 2024, and Barycela, a second-generation varicella vaccine that received WHO prequalification in 2023. The company also develops gene-recombinant therapies for rare diseases, notably Hunterase for Hunter syndrome and GreenGene F for hemophilia, with GreenGene F approved in China in 2021. GC Biopharma serves hospitals, clinics, pharmacies, and wholesalers in South Korea and international markets, including the United States, China, and countries in Latin America and Southeast Asia. The company operates subsidiaries such as GC Biopharma USA for North American sales and GC DO BRASIL for South American market expansion. It maintains a research and development focus on next-generation vaccines, including a shingles vaccine in clinical trials, and rare disease therapeutics.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage gcbiopharma.com
Sector Healthcare IR page gcbiopharma.com/kor/index.do
Tags
blood products, vaccines, rare disease therapeutics, hemophilia, hunter syndrome, influenza vaccines, varicella vaccines, immunoglobulins, gene-recombinant drugs, otc medications, ALYGLO, Barycela, Hunterase, GreenGene F, GC Biopharma USA, GC DO BRASIL, Curevo Inc., GC Biopharma Corp., GC Biopharma, IVIG-SN, Hepabig, EUGAMMA, GCFLU, GC1123B, GC1130A, GC1134A, GC4006A, GC3111B, MG1111D, GC3107A, GCC5694A, Nokxaban, Glazia, Livmarli, Lynex, Dr.PNT, Youthfill, Fillode, DuraGen, LaraShot Q, NovaStem BC Kit, Inibo, GC Wellness, GC Biopharma USA Inc., GC DO BRASIL CONSULTORIA DE NEGÓCIOS LTDA
Press page gcbiopharma.com/kor

Metrics

Valuation  
Market cap ₩ 1.418T
Market cap (USD) $ 1.044B
P/E -27.75
PEG —
P/BV 1.15
P/S 0.72
P/OCF 7.70
P/FCF 16.16
Dividend yield —
Turnover / mcap —
Returns  
ROE -0.38%
ROI -0.38%
ROIC 4.3%
Profit margin -0.23%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 1.991T 1.68T 1.627T 1.711T 1.538T 1.504T 1.37T 1.335T 1.288T 1.198T 1.048T 975.327B 888.168B
Net profit -4.674B -26.28B -26.632B 65.453B 123.212B 81.049B -3.638B 34.429B 53.247B 62.97B 94.967B 83.945B 70.066B
Free cash flow 27.101B -85.452B -84.56B 61.158B 23.658B -46.902B -87.163B -26.976B 28.386B -82.411B -75.908B -1.712B -53.894B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 132.565K 172.717K — — — — — — — — — — —
Price performance 12m -0.23 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 345B 368B 391B 405B 424B 425B 414B 453B 387B 403B
↳ YoY growth +19.6% +6.7% +6.3% +3.6% +4.6% +0.2% -2.6% +9.5% -14.7% +4.2%
↳ 5y CAGR +8.9% +10.4% +8.0% +4.2% +2.4% +3.0% -0.9% -1.0%
Other receivables (KRW) — — — — — — 19.8B 16.3B 21.4B 6.85B
Borrowings, current (KRW) 13.8B — — — — — 187B 518B 378B 609B
Borrowings, non-current (KRW) — — — — — — 279B 84.9B 340B 254B
Lease liabilities (KRW) — — — 76.8B 77.9B 101B 109B 121B 111B 120B
Cash and deposits (KRW) 56.9B 171B 96.6B 98.5B 232B 186B 105B 49.7B 22.6B 49.4B
Intangible assets (KRW) 73.6B 87.9B 101B 103B 110B 277B 312B 338B 307B 337B
Right-of-use assets (KRW) — — — 77.1B 77.4B 101B 108B 125B 111B 116B
Net debt (borrowings + leases - cash) (KRW) -43.2B — — — — — 470B 589B 806B 933B
Cash flow detail
Operating cash flow (KRW) -1.74B 57.9B 14.4B 40.3B 36B 126B 119B -5.47B -53.5B 99.5B
Purchases of property, plant and equipment (KRW) -80.7B -29.5B -41.4B -127B -82.9B -102B -58B -79.1B -32B -72.4B
Purchases of intangible assets (KRW) -18B -26.1B -23.6B -20.2B -18.5B -21.2B -36.7B -46.9B -10.4B -32.9B
Dividends paid (cash effect) (KRW) -20.5B -15.3B -15.3B -12.4B -12.7B -18.5B -24B -24.8B -19.5B -18.8B
Share buybacks (cash effect) (KRW) -21.8B -538M — — — — — — — —
Interest paid (cash effect) (KRW) -4.59B -5.83B -6.55B -7.06B -9.73B -13.5B -19.4B -24.1B -38.1B -38.3B
Income taxes paid (cash effect) (KRW) -43.3B -15B -15.4B -17.8B -8.98B -18.9B -37.3B -19B -2.47B -11.1B
Free cash flow (OCF - PPE - intangibles) (KRW) -100B 2.31B -50.6B -107B -65.4B 2.44B 24.5B -131B -95.9B -5.82B
Income detail
Total comprehensive income (KRW) 66.8B 65.4B 29.8B -14.8B 88.1B 139B 83.6B -3.26B -50.5B -42.9B
Comprehensive income to owners (KRW) 65.1B 61.6B 30.8B -5.6B 80.1B 125B 74.7B -7.99B -33.2B -18.1B
Reported Mar 31, 2017 Jun 18, 2018 Apr 1, 2019 Mar 30, 2020 Apr 28, 2021 Mar 20, 2024 Mar 18, 2025 Mar 18, 2025 Mar 18, 2025 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

단일판매ㆍ공급계약체결 Bull 3 Bear 0 Order/contract
[기재정정]단일판매ㆍ공급계약체결 Bull 2 Bear 0 Order/contract

Prompts

GC Biopharma Corp. (ticker 006280), listed in South Korea.

ETFs Holding GC Biopharma Corp.

ETF Weight in ETF Shares Market value As of
AVEE 0.06% 737 $ 72.512K Nov 16, 2026
AVES 0.03% 4,293 $ 422.38K Nov 16, 2026
DFEV 0.01% 2,853 $ 300.214K Nov 12, 2026
AVEM 0.01% 26,353 $ 2.593M Nov 16, 2026
DFSE 0.01% 541 $ 56.928K Nov 12, 2026
DFEM 0.01% 7,177 $ 755.218K Nov 12, 2026
DFAE 0.01% 5,347 $ 562.652K Nov 12, 2026
DFAX 0.00% 4,813 $ 506.46K Nov 12, 2026
DEXC 0.00% 77 $ 8,102.52 Nov 12, 2026
AVXC 0.00% 101 $ 9,937.19 Nov 16, 2026